You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Indolent NHL

Showing 1 - 25 of 9,486
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022

Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Indolent B-cell Non-Hodgkin's Lymphoma
  • Anjo, Aichi, Japan
  • +29 more
Dec 10, 2021

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma

Completed
Has Results
  • Follicular Lymphoma (FL/Indolent NHL)
  • +4 more
  • Huntsville, Alabama
  • +22 more
Apr 1, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (Fludarabine, Cyclophosphamide, JCAR017)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Santa Monica, California
  • +36 more
Jan 25, 2023

CLL/SLL, NHL, Mantle Cell Lymphoma Trial in United States (SYNCAR-001, STK-009, Cyclophosphamide)

Recruiting
  • CLL/SLL
  • +6 more
  • Duarte, California
  • +4 more
Jan 12, 2023

Hematological Malignancies Trial in Beijing, Tianjin (TQB3820 tablets)

Recruiting
  • Hematological Malignancies
  • TQB3820 tablets
  • Beijing, Beijing, China
  • +1 more
Sep 18, 2021

Non-Hodgkin's Lymphoma Trial in United States (fludarabine and rituximab, fludarabine, rituximab, pixantrone)

Withdrawn
  • Non-Hodgkin's Lymphoma
  • fludarabine and rituximab
  • fludarabine, rituximab, pixantrone
  • Muscle Shoals, Alabama
  • +7 more
Oct 2, 2020

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023

    NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

    Recruiting
    • NHL
    • NHL, Relapsed, Adult
    • Birmingham, Alabama
    • +4 more
    May 31, 2023

    SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • +2 more
      • (no location specified)
      Jun 22, 2023

      Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

      Recruiting
      • Follicular B-cell Non-Hodgkin's Lymphoma
      • +7 more
      • MB-106
      • Orange, California
      • +3 more
      Nov 1, 2022

      Refractory Indolent Adult Non-Hodgkin Lymphoma Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

      Recruiting
      • Refractory Indolent Adult Non-Hodgkin Lymphoma
      • CD19 CAR-T
      • +4 more
      • Shijiazhuang, Hebei, China
        No.2 Hospital of Hebei Medical University
      Nov 11, 2020

      Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

      Recruiting
      • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
      • BAFFR-CAR T cells
      • Duarte, California
        City of Hope Medical Center
      Oct 18, 2022

      Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

      Completed
      • Grade 3a Follicular Lymphoma
      • +9 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 31, 2023

      B-cell NHL, CLL Trial (CARCIK-CD19)

      Not yet recruiting
      • B-cell NHL
      • CLL
      • CARCIK-CD19
      • (no location specified)
      May 19, 2023

      Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

      Recruiting
      • Follicular Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

      Not yet recruiting
      • NK/T Cell Lymphoma
      • +2 more
      • Guangzhou, Guangdong, China
      • +1 more
      Jan 12, 2023

      Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

      Recruiting
      • Recurrent Acute Lymphoblastic Leukemia
      • +15 more
      • Anti-CD19/CD20/CD22 CAR T-Cells
      • +2 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Nov 4, 2022

      Auto/Allo Tandem Transplant for Relapsed B-NHL

      Completed
      • Non Hodgkin Lymphoma
      • auto transplant followed by allo transplant
      • (no location specified)
      Oct 24, 2022

      Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • BTK inhibitor
      • PD-1 inhibitor
      • Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      May 20, 2023

      Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

      Recruiting
      • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
      • TAK-007
      • Chemotherapy Agents
      • Birmingham, Alabama
      • +18 more
      Aug 17, 2022